canada tirzepatide B.C. limits sale of 2 more diabetes drugs used for weight loss Health Canada approves Mounjaro (tirzepatide)

[DOI] [PubMed] [Google Scholar] 98.Saari JT

While GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists cannot selectively reduce belly fat, clinical evidence demonstrates they promote significant overall weight loss that includes meaningful reductions in both subcutaneous and visceral abdominal fat

Elevated LDH levels, pointing to tissue damage and red blood cell breakdown

Research observations may include increased appetite, energy fluctuations and occasional discomfort

Let us look at what the trials found

Difficulty with Muscle Growth : Achieving muscle growth and maintaining muscle mass can be challenging, especially as we age or due to hormonal imbalances